A NOVEL SCREEN FOR INHIBITORS OF FUNGAL GPI-ANCHORING

Information

  • Research Project
  • 6442431
  • ApplicationId
    6442431
  • Core Project Number
    R43AI048337
  • Full Project Number
    1R43AI048337-01A2
  • Serial Number
    48337
  • FOA Number
  • Sub Project Id
  • Project Start Date
    2/15/2002 - 23 years ago
  • Project End Date
    2/14/2003 - 22 years ago
  • Program Officer Name
    DUNCAN, RORY A.
  • Budget Start Date
    2/15/2002 - 23 years ago
  • Budget End Date
    2/14/2003 - 22 years ago
  • Fiscal Year
    2002
  • Support Year
    1
  • Suffix
    A2
  • Award Notice Date
    2/12/2002 - 23 years ago
Organizations

A NOVEL SCREEN FOR INHIBITORS OF FUNGAL GPI-ANCHORING

DESCRIPTION (provided by applicant):Perhaps the most striking difference between fungal cells and human cells is that fungal cells are encased in a wall that protects them from a hostile external environment. The cell wall plays a dynamic role in all aspects of fungal physiology. The fact that human cells lack a cell wall and the underlying biosynthetic and regulatory machinery to make the wall, suggests that drugs targeting cell-wall synthesis and assembly will be safe and specific antifungals. Current treatments include Amphotericin B and a variety of azoles that inhibit membrane-sterol biosynthesis. Unfortunately, Amphotericin B is toxic to humans and clinical resistance to azoles is increasing. These observations underscore the clear need for new antifungals. In this Phase I SBIR application, we propose to develop a novel screen that targets an essential step in fungal cell-wall assembly, namely, the extracellular anchorage of GPI-class mannoproteins. This will be accomplished in two specific aims: 1). Development of a screen to detect inhibitors of GPI-mannoprotein anchoring into the cell wall; 2). Screening of extracts for inhibitors using the assay developed in Aim One. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    100000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
    NIAID:100000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    MYCOLOGICS, INC.
  • Organization Department
  • Organization DUNS
    190042098
  • Organization City
    AURORA
  • Organization State
    CO
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    80045
  • Organization District
    UNITED STATES